Cariprazine confirmed efficacy in the treatment of schizophrenia

At the 28th annual meeting European psychiatric Association (EPA) presented new data on the use of cariprazine in the treatment of negative symptoms of schizophrenia. During the observation study, which was conducted in the outpatient psychiatric medical institutions, confirmed the positive effect of the drug reduced the severity of negative symptoms of schizophrenia in those patients for whom previous therapy was ineffective, and proven favorable safety profile of the drug. The study also showed that the influence of cariprazine on changes in heart rate and QT interval – minimal, comparable to placebo. In addition, a retrospective analysis of the use of cariprazine of risperidone and showed that only cariprazine had a positive effect on negative symptoms in patients during the exacerbation of the disease.

When conducting double-blind studies cariprazine already proved its effectiveness in the treatment of all symptoms of schizophrenia, however, it was important to obtain data of real clinical practice to assess the impact of the drug on patients in their everyday life. Held 16-week observational study involving 116 patients in Latvia. The results showed that cariprazine had a positive effect on reducing negative symptoms of schizophrenia in those patients who suffered to them earlier, but had not received the desired response to therapy. Also when switching to treatment with cariprazine, gradually decreased the severity of existing side effects of previous therapy, showed no significant weight changes, indicating the high safety profile of the drug. It is important to note that most doctors were extremely satisfied with the effectiveness and good tolerability cariprazine.

Also at the conference, EPA was provided with the following data:

1. Long-term treatment with antipsychotics is indicated for all patients with schizophrenia. These drugs can be very effective, but the treatment they may bring some side effects, in particular the complications of the heart. In connection with this was a retrospective analysis of the influence of kapronasia on the cardiovascular system. He showed that the effects of the drug on the parameters of the heart generally comparable with placebo. Heart rate variability and QT interval were minimal, the incidence of side effects associated with the cardiovascular system, as well as associated with the cases of termination of treatment are extremely rare.

2. According to a retrospective analysis of the use cariprazine and risperidone in the treatment of acute and primary negative symptoms of schizophrenia, both drugs showed the same efficacy in the fight against the common symptoms of acute schizophrenia. But only cariprazine demonstrated positive effects on reducing negative symptoms in patients during the acute phase of the disease. Also, this drug has shown greater efficacy in the treatment of patients with predominant negative symptoms of schizophrenia.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]